Dr. James Berenson, president of the Institute for Myeloma and Bone Cancer Research, updates us on the state of Myeloma treatment from the ASCO meeting in June 2011. Dr. Berenson tells us that life with Myeloma is now "a marathon, not a sprint" and describes the shifting focus to quality-of-life issues related to treatment. Topics in this interview include combination drug therapies and clinical trials for drugs Zometa and Xgeva. Dr. Berenson also touches on how quality-of-life issues should impact a patient's consideration of bone-marrow transplant. Overall, he offers an upbeat appraisal for patients living longer and better lives with Multiple Myeloma.